In the last quarter of 2024, QUARTET continued to grow and support the delivery of high-quality radiotherapy across trials from the SIOP Europe Clinical Trial Study Groups such as the Brain Tumour Group, EpSSG, Euro-Ewing Consortium (EEC), RT-SG, and SIOPEN. As a result of the ever-increasing network and portfolio of projects, 2024 saw the launch of the QUARTET Research Leads Council and new working groups for particle therapy and image-guided/adaptive radiotherapy.
Site RTQA approvals and individual case reviews of radiotherapy treatment plans for patients in the FaR-RMS (EpSSG), HRMB (SIOP Europe Brain Tumour Group), HR-NBL2 (SIOPEN), and LINES (SIOPEN) are ongoing – with more than 160 site approvals across 24 countries and over 700 patient reviews completed. We are happy to report that site approvals for INTER-EWING-1 (EEC) have now also begun; with the first patient anticipated early next year.
QUARTET is collaborating with the radiotherapy committees from the trial and European Clinical Trial Study Groups to produce extra resources and guideline updates, to better support centres to deliver high-quality radiotherapy for children and adolescents.
Please come and join us at the SIOP Europe Annual Meeting in May to see some of the latest results.
As always, more information can be found on the QUARTET website, including an updated list and links to all our publications and other outputs of interest.
